Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo

Molecular Medicine Reports

Volumn 5, Issue 1, 2012, Pages 282-286

  Chien, Su Yu ^a   Kuo, Shou Jen ^a,b   Chen, Yao Li ^a,b   Chen, Dar Ren ^a,b   Cheng, Chun Yuan ^a,b   Su, Chin Cheng ^a,b,c  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c MINGDAO UNIVERSITY   (Taiwan)

Author keywords

Bax; Caspase 3; CD31; In vivo; J5 cells; Tanshinone IIA

Indexed keywords

CASPASE 3; CD31 ANTIGEN; FLUOROURACIL; PROTEIN BAX; TANSHINONE IIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIGENS, CD31; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL LINE, TUMOR; DITERPENES, ABIETANE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS;

EID: 84855236222     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.631     Document Type: Article

References (18)

1. Department of Health, Executive Yuan: Statistics of Causes of Death, 2007. Taipei, Taiwan R.O.C, pp34-46, 2008.
2. Leung TW and Johnson PJ: Systemic therapy for hepatocellular carcinoma. Semin Oncol 28: 514-520, 2001. (Pubitemid 32959597)
3. Kucuk O: Chemoprevention of prostate cancer. Cancer Metastasis Rev 21: 111-124, 2002.
4. Che AJ, Zhang JY, Li CH, Chen XF, Hu ZD and Chen XG: Separation and determination of active components in Radix Salviae miltiorrhizae and its medicinal preparations by nonaqueous capillary electrophoresis. J Sep Sci 27: 569-575, 2004. (Pubitemid 38735645)
5. Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359, 2005. (Pubitemid 41643896)
6. Jang SI, Kim HJ, Kim YJ, Jeong SI and You YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542: 1-7, 2006.
7. Li W, Li J, Ashok M, Wu R, Chen D, Yang L, Yang H, Tracey KJ, Wang P, Sama AE and Wang H: A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 78: 3856-3864, 2007. (Pubitemid 46417655)
8. Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD and Huang RW: Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J Biomed Sci 13: 813-823, 2006. (Pubitemid 44900653)
9. Su CC and Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 22: 357-361, 2008.
10. Su CC, Chen GW, Kang JC and Chan MH: Growth inhibition and apoptosis induction by tanshinone IIA in human colon adenocarcinoma cells. Planta Med 74: 1357-1362, 2008.
11. Lin R, Wang WR, Liu JT, Yang GD and Han CJ: Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J Ethnopharmacol 108: 217-222, 2006. (Pubitemid 44635028)
12. Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47: 1836-1841, 2003. (Pubitemid 36637803)
13. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF and Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol 10: 2024-2028, 2004. (Pubitemid 39106951)
14. Zhai XM, He SX, Ren MD, Chen JH, Wang ZL, Han M and Hou HL: Effect of Tanshinone II A on expression of EGF and EGFR in hepatocellular carcinoma cell line SMMC-7721. Zhejiang Da Xue Xue Bao Yi Xue Ban 38: 163-169, 2009.
15. Lee WY, Liu KW and Yeung JH: Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 285: 46-57, 2009.
16. Yuxian X, Feng T, Ren L and Zhengcai L: Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori 95: 789-795, 2009.
17. Cheng CY and Su CC: Tanshinone IIA inhibits Hep-J5 cells by increasing calreticulin, caspase 12 and GADD153 protein expression. Int J Mol Med 26: 379-385, 2010.
18. Li Q, Wang Y, Feng N, Fan Z, Sun J and Nan Y: Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma. J Drug Target 16: 725-732, 2008.